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doi:10.1016/j.jmii.2011.01.019Background: The antinuclear antibody (ANA) test is the most commonly used test to screen for
autoimmune diseases. However, only a limited numbers of studies have addressed the charac-
teristics of patients positive for ANA. In this study, we aimed to clarify the relationship
between initial presentations, ANA titer, and final diagnoses.
Methods: Patients who visited National Taiwan University Hospital and received a first ANA test
were enrolled and then followed for a further 6 months. The symptoms and signs at the time of
ANA testing, ANA titers, and the final diagnoses were recorded and analyzed.
Results: A total of 355 patients were positive for ANA. Joint pain was the most common initial
presentation at the time of ANA testing. Compared with the patients with low ANA titers
(<1:640), those with high ANA titers (1:640) were more susceptible to autoimmune diseases.
More importantly, of the patients with initial presentations of joint pain, fever, abnormal urinal-
ysis, or skin rash/skin tightness, autoimmune diseases were more frequently diagnosed in those
with high ANA titers than with low ANA titers (p< 0.05). In addition, both anti-double strand
DNA antibodies and anti-extractable nuclear antibodies were more commonly detected in
patients with high ANA titers.nt of Pediatrics, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10002,
tw (B.-L. Chiang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Diagnosis of patients positive for ANA test 223Table 1 The initial presentation
Initial presentations
Hematologic problems
Abnormal urinalysis findings
Liver function impairment
Joint pain
Muscle weakness/myalgia
Oral lesions
Raynaud’s phenomenon
Skin presentationsa
Sicca syndrome
Lymphadenopathy
Cardiopulmonary s/s
Neuropsychologic problems
Fever
Others
a Skin presentations included skin
ANAZ antinuclear antibody; s/sZ sConclusions: A high ANA titer seems to be a useful biomarker for the diagnosis of autoimmune
diseases, especially for patients presenting with joint pain, fever, abnormal urinalysis, or skin
rash/skin tightness.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Autoantibodies directed against nuclear and cytoplasmic
components of tissue cells have been known to play an
important role in autoimmune diseases for several
decades.1,2 The methods used to detect antinuclear anti-
bodies (ANAs) evolved from the lupus erythematosus cell
phenomenon into indirect immunofluorescence assay and
enzyme-linked immunosorbent assay. At present, the ANA
test is the most commonly used autoantibody test and also
one of the most over ordered tests in the clinical labora-
tory.3 Many clinicians use the ANA test to screen for auto-
immune diseases, including systemic lupus erythematosus
(SLE), Sjo¨gren’s syndrome (SS), systemic sclerosis (SSc), and
mixed connective tissue disease. However, ANA can be
detected not only in autoimmune diseases but also in other
medical conditions, such as liver disease, malignancy,
chronic infections, and thyroid disease.3
Although many studies have reported the distribution of
various ANA titers, patterns, and associated diseases,
there are only limited data available on the relationship
between initial presentations, different ANA titers, and
final diagnoses. In addition, Vaile et al.4 concluded that
setting a higher ANA titer cutoff point (1:640) is of limited
benefit to predict autoimmune disease. The purpose of our
study is to clarify the relationship between initial presen-
tations, ANA titers, and final diagnoses and combined with
initial presentations, to determine whether the patients
with high ANA titers are more susceptible to autoimmune
diseases.s of patients positive for ANA t
Total (nZ 355), n (%)
35 (9.9)
12 (3.4)
36 (10.1)
132 (37.2)
7 (2.0)
23 (6.5)
14 (3.9)
51 (14.4)
44 (12.4)
7 (2.0)
17 (4.8)
21 (5.9)
28 (7.9)
9 (2.5)
rash or skin tightness.
ymptoms/signs.Material and methods
From September 2007 to March 2008, the patients who
visited National Taiwan University Hospital and received
a first ANA test were enrolled. ANA were detected by
immunofluorescence assay techniques using human
epithelial tumor cell lines, HEp-2 cells as substrate, and an
immunoglobulin G-specific conjugate to reveal ANA
binding. Because more than 30% of normal individuals have
been found to have low ANA titers,5 the patients with
negative or positive results at a titer of 1:40 were excluded.
In our laboratory, an ANA titer of 1:640 is defined as a “high
titer” because of a 0.5% prevalence of positives in normal
individuals. Therefore, we divided the patients into a high
titer group (1:640) and low titer group (<1:640). The
initial symptoms and signs on presentation were recorded
and divided into 14 categories (shown in Table 1). Tests for
anti-extractable nuclear antigen (anti-ENA) or anti-double
strand DNA (anti-dsDNA) were also performed subsequently
in some patients. The patients positive for ANA were fol-
lowed for a further 6 months. The final diagnoses were then
classified into three major categories (shown in Table 2);
autoimmune diseases, nonautoimmune diseases, and not
confirmed. Systemic autoimmune diseases and organ-
specific autoimmune diseases were categorized together as
autoimmune diseases. The nonautoimmune diseases were
subdivided into seven categories.
All statistical analyses were performed using SPSS soft-
ware version 15.0. (SPSS Inc., Chicago, IL, USA). Differences
between groups in categorical variables were examinedest
Adult (nZ 320), n (%) Child (nZ 35), n (%)
32 (10) 3 (8.6)
10 (3.1) 2 (5.7)
34 (10.6) 2 (5.7)
116 (36.4) 16 (45.7)
5 (1.6) 2 (5.7)
22 (6.9) 1 (2.9)
13 (4.1) 1 (2.9)
38 (11.9) 13 (37.1)
44 (13.8) 0 (0)
6 (1.9) 1 (2.9)
17 (5.3) 0 (0)
20 (6.3) 1 (2.9)
24 (7.5) 4 (11.4)
9 (2.8) 0 (0)
Table 2 Comparison of the disease categories between
the high- and low-titer groups
Disease categories ANA 1:640
(nZ 118), (%)
ANA< 1:640
(nZ 237), (%)
Autoimmune diseases 84 (71.2)a 83 (35.0)
Nonautoimmune disease 19 (16.1) 62 (26.2)
1. Hepatic diseases 4 6
2. Malignancy 3 6
3. Dermatologic diseases 1 14
4. Musculoskeletal diseases 3 10
5. Hematologic diseases 1 0
6. Infectious diseases 4 14
7. Others 3 12
Not confirmed 15 (12.7) 92 (38.8)a
a A p value less than 0.05 was considered to be statistically
significant.
Hepatic diseases did not include autoimmune hepatitis and viral
hepatitis. The diagnosis of skin rash related to systemic auto-
immune disease was excluded from the dermatologic diseases.
Similarly, the diagnosis of musculoskeletal symptoms
(arthralgia, muscle pain, and so on) associated with other
autoimmune diseases were excluded from musculoskeletal
disease. Hematologic abnormalities unrelated to autoimmune
diseases were categorized as hematologic diseases. Infectious
diseases included chronic viral hepatitis and other microor-
ganisms confirmed by serologic evidence or culture.
ANAZ antinuclear antibody.
Table 3 Frequency of ANA patterns and final diagnoses (nZ 55
Diagnosis Homogeneous
(nZ 149), n (%)
Speckled
(nZ 60), n (
No conclusion 45 (29.5) 18 (30.0)
Nonautoimmune disease 31 (24.8) 13 (21.6)
Autoimmune disease 73 (45.7) 29 (48.4)
SLE 21 10
SCLE 1 2
Rheumatoid arthritis 9 4
Systemic sclerosis 1 1
Sjo¨gren’s syndrome 11 3
Dermatomyositis 2 0
Vasculitis 3 1
MCTD 0 4
Ankylosing spondylitis 0 1
Raynaud’s syndrome 1 0
ITP 4 0
Autoimmune hepatitis 1 2
Autoimmune pancreatitis 1 0
Autoimmune thyroiditis 6 0
Lichen planus 6 0
Others 6 1
a Mixed type: two or more of the other four patterns (homogeneou
ANAZ antinuclear antibody; ITPZ idiopathic thrombocytopenic pur
lupus erythematosus; SCLEZ subacute cutaneous lupus erythematosu
224 K.-Y. Wang et al.using Fisher’s exact test or the Chi-square test. A p value
less than 0.05 was considered statistically significant.
Results
Characteristics of the patient population
A total of 355 patients (84 males and 271 females) whose
first ANA tests were positive and higher than 1:40 were
enrolled and followed for a further 6 months. Three
hundred twenty of them were adults, ranging in age from
19.7 to 84.6 years with the mean age being 49.8 years. The
remaining patients were children, ranging in age from 0.6
to 17.9 years with the mean age being 11.1 years.
The initial presentations for ANA tests
As shown in Table 1, the most common initial presentations
in the 355 patients were joint pain (37.2%), followed by skin
presentations (14.4%) and sicca syndrome (12.4%). The
adult patients were more likely to present with sicca
syndrome but less likely to have skin involvement.
Distribution of the ANA patterns and associated
final diagnoses
Table 3 shows the ANA immunofluorescent patterns and the
finaldiagnoses.Themostcommonpatternwas“homogeneous”
(42%), followed by “mixed” (23.9%), “speckled” (16.9%),
“centromere” (9.3%), and“nucleolar” (7.9%). In contrast to the
other four patterns, the “nucleolar” pattern was less associ-
ated with autoimmune diseases (45e55% vs. 10.7%).)
%)
Centromere
(nZ 33), n (%)
Nucleolar
(nZ 28), n (%)
Mixed
(nZ 85), n (%)a
12 (36.3) 12 (42.9) 20 (23.5)
6 (18.2) 13 (46.4) 18 (21.2)
15 (45.5) 3 (10.7) 47 (55.3)
3 1 14
0 0 0
0 0 3
2 0 3
7 0 12
0 0 1
1 0 1
0 0 0
1 0 2
0 0 1
0 0 2
1 1 5
0 0 0
0 0 0
0 0 3
0 1 0
s, speckled, centromere, and nucleolar).
pura; MCTDZmixed connective tissue disease; SLEZ systemic
s.
Table 4 The final diagnoses of 167 patients who had
autoimmune diseases after follow-up for 6 months
Diagnoses ANA 1:640
(nZ 90),
n (%)
ANA< 1:640
(nZ 77),
n (%)
Systemic lupus erythematosus 40 (44.4) 9 (11.7)
Subacute cutaneous lupus
erythematosus
1 (1.1) 2 (2.6)
Rheumatoid arthritis 3 (3.3) 13 (16.9)
Sjo¨gren’s syndrome 15 (16.7) 18 (23.4)
Systemic sclerosis 6 (6.7) 1 (1.3)
Raynaud’s syndrome 1 (1.1) 1 (1.3)
Vasculitis 3 (3.3) 3 (3.9)
Idiopathic thrombocytopenic
purpura
1 (1.1) 5 (6.5)
Mixed connective tissue disease 4 (4.5) 0 (0)
Ankylosing spondylitis 1 (1.1) 3 (3.9)
Dermatomyositis 1 (1.1) 2 (2.6)
Lichen planus 1 (1.1) 8 (10.4)
Autoimmune hepatitis 6 (6.7) 4 (5.2)
Autoimmune pancreatitis 0 (0) 1 (1.3)
Autoimmune thyroiditis 6 (6.7) 0 (0)
Others 1 (1.1) 7 (9.0)
Behcet’s disease 0 2
Antiphospholipid syndrome 0 1
Diagnosis of patients positive for ANA test 225The distribution of various ANA titers
Figure 1 demonstrates that among the 355 patients positive
for ANA, 118 (33.2%) had an ANA titer 1:640 and 237 (66.8%)
had an ANA titer < 1:640. Compared with the male patients
(12/84, 14.2%), a higher proportion of the female patients
(77/271, 28.4%) were found to have an ANA titer  1:1,280.
The disease categories of patients with positive
ANA test
The final diagnoses of the patients with positive ANA tests
after 6 months of follow-up are shown in Table 2. One
hundred sixty-seven patients (47.0%) had autoimmune
diseases, and 81 (22.8%) had nonautoimmune diseases.
However, no confirmed diagnoses could be made in the
remaining 107 (30.1%) patients. Compared with the
patients with low ANA titers, those with high ANA titers
were highly associated with autoimmune diseases (71.2%
vs. 35.0%). The detailed diagnoses of the 167 patients
classified as autoimmune disease are shown in Table 4. The
most common autoimmune disease in the high titer group
was SLE, found in 40 of the 90 patients (44.4%), followed by
SS (16.7%), SSc (6.7%), autoimmune hepatitis (6.7%), and
autoimmune thyroiditis (6.7%). However, SS (23.4%) was the
most common autoimmune disease in the 77 patients withFigure 1. Frequency of ANA titer in all 355 patients. Among
the 355 patients positive for ANA, 118 (33.2%) had an ANA
titer 1:640 and 237 (66.8%) had an ANA titer＜ 1:640.
Compared with the male patients (blank bar), a higher
proportion of the female patients (77/271, 28.4%) were found
to have an ANA titer 1:1,280. ANAZ antinuclear antibody.
Evans syndrome 1 0
Multiple sclerosis 0 1
Palindromic rheumatism 0 1
Dry eye syndrome 0 2
ANAZ antinuclear antibody.low ANA titers, followed by rheumatoid arthritis (16.9%),
SLE (11.7%), lichen planus (10.4%), and idiopathic throm-
bocytopenic purpura (6.5%). Most of the patients with SLE,
SSc, mixed connective tissue disease, autoimmune
thyroiditis, and autoimmune hepatitis had high ANA titers
(81.6%, 85.7%, 100%, 100%, and 66.7%, respectively). In
contrast, most of the patients with rheumatoid arthritis,
lichen planus, and idiopathic thrombocytopenic purpura
had low ANA titers (81.3%, 88.9%, and 83.3%, respectively).
In addition, Table 2 demonstrates the categories of
nonautoimmune diseases. In contrast to the patients who
had autoimmune diseases, most of the patients with non-
autoimmune diseases (62/81, 76.5%) had ANA titers lower
than 1:640. Among the nonautoimmune diseases, infectious
diseases accounted for the highest proportion (22.2%),
followed by dermatologic diseases (18.5%) and musculo-
skeletal diseases (16.0%). Hepatic diseases included five
patients with chronic hepatitis of unknown origin, one
patient with Dubin-Johnson syndrome, one patient with
acute nonviral hepatitis, and three patients with nonviral
liver cirrhosis. Nine adult patients (three in the high titer
group and six in the low titer group) had malignancy, but
none of the children had malignancies at the end of our
study. The diagnosis of these nine patients included mye-
lodysplastic syndrome, lymphoma, leukemia, pancreatic
cancer, colon cancer, cholangiocarcinoma, and multiple
myeloma (not shown in the table). Infectious diseases
included chronic hepatitis B or C infection, infectious
226 K.-Y. Wang et al.mononucleosis, and tuberculosis. Nevertheless, it must be
noted that 92 (38.8%) of the 237 patients with low ANA
titers and 15 (12.7%) of the 118 patients with high ANA
titers had no confirmed diagnoses during the 6 months of
observation.
The association among initial presentations, ANA
titers, and autoimmune diseases
As can be seen in Table 5, 72.5% of the patients with high
ANA titers and joint pain and 37% of the patients with low
ANA titer and joint pain; 100% of the patients with high ANA
titers and fever and 12.5% of the patients with low ANA
titers and fever; 100% of the patients with high ANA titers
and abnormal urinalysis findings and 14.3% of the patients
with low ANA titers and abnormal urinalysis findings; and
100% of the patients with high ANA titer and skin presen-
tations and 14.3% of the patients with low ANA titer and
skin presentations were finally confirmed with autoimmune
diseases. Combined, for the patients with initial presenta-
tions of joint pain, fever, abnormal urinalysis findings, or
skin presentations, those who had high ANA titers were
significantly more susceptible to autoimmune diseases than
those with low ANA titers.Table 5 The prevalence of autoimmune diseases among initial
Initial presentations ANA titer n
Hematologic problems <1:640 19
1:640 16
Joint pain <1:640 92
1:640 40
Fever <1:640 16
1:640 12
Oral lesion <1:640 19
1:640 4
Raynaud’s phenomenon <1:640 3
1:640 11
Lymphadenopathy <1:640 3
1:640 3
Liver function impairment <1:640 22
1:640 14
Abnormal urinalysis finding <1:640 7
1:640 5
Skin presentations <1:640 29
1:640 22
Muscle weakness/myalgia <1:640 4
1:640 3
Sicca syndrome <1:640 26
1:640 18
Cardiopulmonary s/s <1:640 10
1:640 7
Neuropsychiatric s/s <1:640 15
1:640 6
The comparison of percentage of autoimmune diseases between high
A p value less than 0.05 was considered to be statistically significant
ANAZ antinuclear antibody; NSZ not significant; s/sZ symptoms/siThe frequency of ANA profiles and specific ENA
Some patients received anti-dsDNA tests and anti-ENA tests
after their first ANA test. Anti-dsDNA testswere performed in
127 patients and 27 (21.2%) were positive. As we expected,
26 (96.2%) of the 27 patients with positive anti-dsDNA tests
were finally diagnosed as SLE (not shown in the table). A total
of 154 patients received anti-ENA tests and 55 (35.7%) of
them showed positive results (shown in Table 6). Among the
55 patients with positive anti-ENA tests, 49 (87.5%) were
found to have autoimmune diseases. Table 7 shows the
components of anti-ENA antibodies in these 49 patients.
Discussion
An ANA test is initially suggested if the clinician feels there is
a reasonable suspicion of SLE based on historical informa-
tion, physical findings, and the results of other laboratory
tests. However, the ANA test has also become a common
screening method for other autoimmune diseases.3,6 Many
studies have confirmed the importance of the ANA test in the
diagnosis of autoimmune diseases and demonstrated the
trend that patients with higher ANA titers are more suscep-
tible to autoimmune diseases. In addition, ANA can also bepresentations and ANA titers
Autoimmune disease p
Yes, n (%) No, n (%)
7 (36.8) 12 (63.2) 0.06
11 (68.7) 5 (31.3)
35 (37.0) 57 (63.0) <0.001
29 (72.5) 11 (27.5)
2 (12.5) 14 (87.5) <0.001
12 (100) 0 (0)
13 (68.4) 6 (31.6) NS
4 (100) 0 (0)
1 (33.3) 2 (66.7) 0.093
10 (90.9) 1 (9.1)
2 (66.6) 1 (33.4) NS
3 (100) 0 (0)
5 (22.7) 17 (77.3) NS
5 (35.7) 9 (64.3)
1 (14.3) 6 (85.7) <0.05
5 (100) 0 (0)
10 (34.5) 19 (65.5) <0.05
15 (68.2) 7 (31.8)
1 (25.0) 3 (75.0) NS
3 (100) 0 (0)
20 (76.9) 6 (23.1) NS
14 (77.8) 4 (22.2)
2 (20.0) 8 (80.0) NS
4 (57.1) 3 (42.9)
2 (13.3) 13 (86.7) NS
3 (50) 3 (50)
- and low-ANA titers is presented as p values.
.
gns.
Table 6 The frequency of anti-ENA antibodies and anti-
dsDNA antibodies between high titer and low titer ANA
Autoantibodies tests ANA 1:640,
n (%)
ANA< 1:640,
n (%)
Anti-dsDNA test nZ 66 nZ 61
Positive 22 (31.8) 5 (8.2)
Autoimmune diseases YesZ 22
NoZ 0
YesZ 4
NoZ 1
Anti-ENA test nZ 76 nZ 78
Positive 41 (53.9) 14 (17.9)
Autoimmune diseases YesZ 38 YesZ 11
SLE 21 3
Sjo¨gren’s syndrome 8 70
MCTD 4 0
Systemic sclerosis 2 0
SCLE 1 0
Raynaud’s syndrome 2 0
Antiphospholipid
syndrome
0 1
Autoimmune diseases NoZ 3 NoZ 3
ANAZ antinuclear antibody; dsDNAZ double-stranded DNA;
ENAZ extractable nuclear antibodies; MCTDZmixed connec-
tive tissue disease; SLEZ systemic lupus erythematosus.
Diagnosis of patients positive for ANA test 227detected in nonautoimmune diseases, such as hepatic
disease, malignancy, chronic infections, or thyroid disease.3
In this study, we collected the patients whose first ANA test
was positive and focused on the relationships between their
initial presentations, immunofluorescence patterns, ANA
titers, and the final diagnoses.
Table 1 summarizes the initial presentations and shows
that joint pain was the most common presentation in
patients with positive ANA tests, both in adults and chil-
dren. This is not surprising because most of the common
autoimmune diseases present with arthritis or arthralgia
during the disease course. For example, about 60% of SLE
patients,7 54e84% of SS,8,9 and 12e66% of SSc10,11 patients
have joint involvement. In our study, only the adult
patients presented with sicca syndrome. This could be
explained by the fact that most of the cases of SS occur inTable 7 The components of anti-ENA antibodies in the patient
Autoantibodies tests SLE SCLE RA Syst
Anti-ENA test 37 2 8 7
Anti-ENA (þ) 25 1 0 2
Anti-RNP (þ) 11 0 0 0
Anti-SSA (þ) 15 1 0 2
Anti-SSB (þ) 10 1 0 1
Anti-SCL70 (þ) 0 0 0 0
Anti-SM (þ) 10 0 0 0
Anti-histone (þ) 0 0 0 0
Anti-Jo1 (þ) 0 0 0 0
ENAZ extractable nuclear antibodies; MCTDZmixed connective tissu
lupus erythematosus; SLEZ systemic lupus erythematosus; RNPZ ri
Syndrome B; SCLZ scleroderma; SMZ Smith.midlife12 but that it is a rare disease in childhood.13
Because many autoimmune diseases have various and
broad-ranging cutaneous manifestations,14 skin presenta-
tions, including skin rash or skin tightness are also
commonly seen in patients with positive ANA tests.
Roberts-Thomson et al.15 reported 5,718 patients who
were positive for ANA with the most common immunofluo-
rescent patterns being homogeneous (39%), speckled (20%),
mixed (17%), nucleolar (8%), Ro (7%), and centromere (4%).
Our results were similar with a slight difference. The most
common patterns were homogeneous (42%), followed by
mixed (23.9%), speckled (16.9%), centromere (9.3%), and
nucleolar (7.9%). Generally, the homogeneous pattern is
linked to SLE and the speckled pattern to sclerodermaor SS.16
However, the homogeneous pattern can be found in many
autoimmune diseases and, in contrast, various ANA patterns
in the same autoimmune disease. Although, the ANA pattern
once played an important role in the prediction of various
autoimmune diseases, it has been replaced by more specific
ANA tests, such as the anti-dsDNA test or anti-ENA test.
Chronic hepatitis C virus and hepatitis B virus infection
were the most common infectious diseases associated with
ANA in our study. Some studies have reported that ANA can
be detected in 21e34% of hepatitis C virus-infected indi-
viduals17e19 and 18.2% of hepatitis B virus-infected
patients.20 Although the mechanism remains unclear,
hepatitis C infection plays an important role in the patho-
genesis of immunologic derangement, which may result in
ANA production.21 Previous studies have reported positive
ANA in up to 27% of patients with malignancies.22e24
Therefore, the possibility of malignant diseases should be
kept in mind despite the strong association between ANA
and autoimmune diseases.
The presence of ANA in cancer may reflect an autoim-
mune response to nuclear antigens, which are perturbed in
cellular transformation25 or because of the higher preva-
lence of both cancer and ANA among the elderly.26 This may
also explain why malignant diseases were only found in the
adults in our study.
Dinser et al.27 reported that elevated ANA titers have
a low positive predictive value of 4% for developing ANA-
associated autoimmune diseases in the absence of clinical
suspicion. In our study, the patients with ANA titers  1:640
and initially presenting with joint pain, fever, abnormals with autoimmune diseases
emic sclerosis MCTD Sjo¨gren’s
syndrome
Raynaud’s
syndrome
4 31 2
4 15 2
4 1 2
3 15 1
0 10 1
0 0 0
2 1 0
0 0 0
0 0 0
e disease; RAZ rheumatoid arthritis; SCLEZ subacute cutaneous
bo-nucleo-protein; SSAZ Sjogren’s Syndrome A; SSBZ Sjogren’s
228 K.-Y. Wang et al.urinalysis findings, or skin presentations were highly associ-
ated with autoimmune diseases. Therefore, these symptoms
may increase the positive predictive value of elevated ANA
titers for autoimmune diseases. In addition, long-term
follow-up may be needed for the patients without definite
diagnosis, especially in those with high ANA titers and pre-
senting with joint pain, fever, abnormal urinalysis finding, or
skin presentations.
The limitation of our study includes the duration of
follow-up and the relatively small case numbers. All the
patients receiving an ANA test were only followed for 6
months, which might not be long enough for an autoim-
mune disease to become established. The definition of
immunofluorescent pattern depended on the judgment of
medical laboratory technologists; thus, the ANA test
reports of the same patients may have been different in
various laboratories. In addition, the diagnosis of autoim-
mune diseases depended on the judgment of physicians
whose background in training and experience were
different. This may have affected the distribution and
classification of the final diagnoses. However, at the least
our study showed the overall distribution of ANA titers,
patterns, and the final results in a medical center.
We found a trend that patients with high ANA titers were
more likely to be associated with autoimmune diseases.
However, there were still a lot of exceptions. An ANA test
should not be used alone to exclude nonautoimmune
diseases without other information. When patients have
ANA titers  1:640 and present with joint pain, fever,
abnormal urinalysis, or skin presentations, long-term
follow-up and other laboratory tests (C3/C4, rheumatoid
factor, and so on) are needed for the final diagnosis.
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